yttrium Y 90 DOTA monoclonal antibody HuPAM4

Known as: Y90 DOTA MOAB HuPAM4, Yttrium Y-90 Clivatuzumab Tetraxetan, IMMU-107 
A radioimmunoconjugate comprised of the humanized monoclonal antibody clivatuzumab, directed against the pancreatic cancer antigen MUC1, that is… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
01220012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A hypertensive man with chronic kidney disease (CKD) secondary to polycystic disease was hospitalized for symptoms related to… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2012
2012
227 Background: A Phase I/II trial was undertaken to evaluate repeated cycles of 90Y-labeled anti-mucin humanized mAb (90Y-hPAM4… (More)
Is this relevant?
2011
2011
240 Background: The90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), is in clinical development in APC… (More)
Is this relevant?
2009
2009
INTRODUCTION A previous report on (68)Ga-1,4,7,10-tetraazacyclodedecane-N,N',N'',N'''-tetraacetic acid (DOTA)-Re(Arg(11))CCMSH… (More)
Is this relevant?
2009
2009
4620 Background: In a phase I study, a single dose of 90Y-labeled anti-mucin humanized antibody, hPAM4 (90Y-hPAM4), led to… (More)
Is this relevant?
2001
2001
UNLABELLED The aim of this study was to examine the effect of rhenium-mediated peptide cyclization on melanoma targeting… (More)
Is this relevant?
2001
2001
Objectives: Radioimmunotherapy studies using IPAM4 have demonstrated significant antitumor effects in mice bearing human… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?